Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Phase 2 Study of Dasatinib (Sprycel) in Patients With Alveolar Soft,Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid,Sarcoma, or Solitary Fibrous Tumor

    About 20% of people with chondrosarcoma responded to the drug (tumor shrinkage by 20%).

    On average people with CS were on the drug for about 4-5 months before it was deemed ineffective though.

    In looking at the criteria for CS patients on the trial, it looks as if Grade I and II CS were allowed on but not Grade III. That is probably not a big deal given Grade II was allowed on, but it was not tested in Grade III pts in this trial.

    I don’t see anything specifically about lung mets in the trial, but again should not make a difference.

    The drug is a cousin of imatinib.
    cancer 2016 dasatinib.pdf